Descriptions of benefits and risks in consent forms for phase 1 oncology trials

New England Journal of Medicine

Volumn 347, Issue 26, 2002, Pages 2134-2140

  Horng, Sam ^a   Emanuel, Ezekiel J ^a   Wilfond, Benjamin ^a   Rackoff, Jonathan ^a   Martz, Karen ^b   Grady, Christine ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; DRUG SAFETY; HUMAN; INFORMED CONSENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH;

BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE I; HUMANS; INFORMED CONSENT; MEDICAL ONCOLOGY; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RISK ASSESSMENT; UNITED STATES;

EID: 0037180808     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsa021182     Document Type: Article

References (30)

1. Phase I trials. In: Levinthal BG, Wittes RE. Research Methods in Clinical Oncology. New York: Raven Press, 1988:41-59.
2. Emanuel EJ. A phase I trial on the ethics of phase I trials. J Clin Oncol 1995;13:1049-51.
3. Lipsett MB. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA 1982;248:941-2.
4. Markman M. The ethical dilemma of phase I clinical trials. CA Cancer J Clin 1986;36:367-9.
5. Miller M. Phase I cancer trials: A collusion of misunderstanding. Hastings Cent Rep 2000;30(4):34-42.
6. Idem. Phase I cancer trials: A crucible of competing priorities. Int Anesthesiol Clin 2001;39(3):13-33.
7. Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology research: A comparison of investigators and institutional review board chairpersons. J Clin Oncol 1992;10:1810-6.
8. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990;1:175-81.
9. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 1986;70:1105-15.
10. Itoh K, Sasaki Y, Miyata Y, et al. Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 1994;34:451-4.
11. Von Hoff D, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991;9:115-22.
12. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: A cross-sectional survey. Lancet 2001;358: 1772-7
13. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995; 13:1062-72. [Erratum, J Clin Oncol 1995;13:2476.]
14. Daugherty CK, Banik DM, Janish L, Ratain MJ. Quantitative analysis of ethical issues in phase I trials: A survey interview study of 144 advanced cancer patients. IRB 2000;22:6-13.
15. Yoder LH, O'Rourke TJ, Etnyre A, Spears DT, Brown TD. Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum 1997;24:891-6.
16. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 2000;18: 421-8. [Erratum, J Clin Oncol 2000;18:1807.
17. Cavalli F, Sessa C. Current issues in phase I trials: New study designs and informed consent procedures. Ann Oncol 1990;10:Suppl 6:147-8.
18. Freedman B. Cohort-specific consent: An honest approach to phase I clinical cancer studies. IRB 1990;12:5-7.
19. Stolberg SG. Teenager's death is shaking up field of human gene-therapy experiments. New York Times. January 27, 2000:A20.
20. Daughtery CK. Impact of therapeutic research on informed consent and the ethics of clinical trials: A medical oncology perspective. J Clin Oncol 1999;17:1601-17.
21. Simes RJ, Tattersall M, Coates AS, Raghavan D, Solomon HJ, Smartt H. Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. BMJ 1986;293:1065-8.
22. Cox K. Informed consent and decision-making: Patients' experiences of the process of recruitment to phase I and II anti-cancer drug trials. Patient Educ Couns 2002;46:31-8.
23. McNeilly PJ, Carome M. Human Subjects Protections Under Multiple Project Assurance (MPA) M-1011. [Letter to Johns Hopkins.] Rockville, Md.: Office for Human Research Protections, National Institutes of Health, July 19, 2001.
24. Cassel C, Stock MC, Wood A, Zapol W, Hellman S, Report of Johns Hopkins University External Review Committee of August 8, 2001. Baltimore: Office of Communications and Public Affairs, Johns Hopkins Medical Institutions, August 2001. (Also available at http://www. hopkinsmedicine.org/external.pdf.)
25. James Bell Associates. Final Report Evaluation of NIH Implementation of Section 491 of the Public Health Service Act, Mandating a Program of Protection for Research Subjects. Bethesda, Md.: Office of Extramural Research, National Institutes of Health, June 1998. (NIH contract no. NO1-OD-2-2109.) (Also available at http://ohrp.osophs.dhhs.gov/hsp_report/hsp_rpt_no_figures.pdf.)
26. Morrow GR. How readable are subject consent forms? JAMA 1980; 244:56-8.
27. Grossman SA, Piantadosi S, Covahey C. Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? J Clin Oncol 1994;12:2211-5.
28. Cancer Centers List. Bethesda, Md.: National Cancer Institute, September 2002., (Accessed December 2, 2002, at http://www3.cancer.gov/ cancercenters/centerslist.html.)
29. New medicines in development for cancer, 2001. Washington, D.C.: Pharmaceutical Research Manufacturers of America, 2001. (Accessed December 2, 2002, at http://www.phrma.org/newmedicines/resources/ cancer01.pdf.)
30. King NMP. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 2000;28:332-43,